Prothena Corporation plc (PRTA)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 11:37AM EDT. Market open.
| Previous close | 20.34 |
| Open | 20.59 |
| Bid | 20.97 x 100 |
| Ask | 21.10 x 100 |
| Day's range | 20.26 - 21.61 |
| 52-week range | 19.65 - 79.65 |
| Volume | |
| Avg. volume | 630,540 |
| Market cap | 1.128B |
| Beta (5Y monthly) | 0.24 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Earnings Preview: Prothena (PRTA) Q1 Earnings Expected to Decline
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Investor's Business Daily
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.
- Zacks
CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug
Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.
© 2024 Yahoo. All rights reserved.